Some mouse studies report that the therapeutic benefit of anti-CTLA-4 depends, at least in part, on Fcγ–receptor-dependent depletion of intratumoral Tregs71, while other studies found that anti-CTLA4 induces proliferation of tumor-associated Tregs in MC38 tumor-bearing mice72. Here, CTLA4 is linked to neoplasm.